Apilimod Compositions and Methods for Using Same
The present invention relates to methods for treating cancer with apilimod and related compositions and methods.
1 - 23 . (canceled)
24 . A method for treating a refractory or recurrent non-Hodgkin's B cell lymphoma in a human subject in need thereof, the method comprising administering a pharmaceutical composition comprising apilimod, or a pharmaceutically acceptable salt thereof, to the subject in a therapeutically effective amount.
25 . The method of claim 24 , wherein the pharmaceutical composition is an oral dosage form.
26 . The method of claim 24 , wherein the non-Hodgkin's B cell lymphoma is selected from diffuse large B cell lymphoma (DLBCL), follicular lymphoma, Burkitt's lymphoma, mediastinal B cell lymphoma, and mantle cell lymphoma.
27 . The method of claim 26 , wherein the non-Hodgkin's B cell lymphoma is DLBCL.
28 . The method of claim 27 , wherein the DLBCL is DLBCL-GCB.
29 . The method of claim 26 , wherein the non-Hodgkin's B cell lymphoma is a follicular lymphoma.
30 . The method of claim 24 , wherein the pharmaceutically acceptable salt is selected from a sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, besylate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (e.g., 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)).
31 . The method of claim 30 , wherein the pharmaceutically acceptable salt is selected from a chloride, mesylate, fumarate, lactate, maleate, pamoate, phosphate, and tartrate.
32 . The method of claim 24 , wherein the method comprises administering the apilimod, or pharmaceutically acceptable salt thereof, in combination with at least one additional active agent.
33 . The method of claim 32 , wherein the at least one additional active agent is administered in the same dosage form as the apilimod, or in a separate dosage form.
34 . The method of claim 32 , wherein the at least one additional active agent is selected from the group consisting of an alkylating agent, an intercalating agent, a tubulin binding agent, a corticosteroid, and combinations thereof.
35 . The method of claim 32 , wherein the at least one additional active agent is selected from the group consisting of ibrutinib, rituximab, doxorubicin, prednisolone, vincristine, velcade, and everolimus, and combinations thereof.
36 . The method of claim 32 , wherein the at least one additional active agent is selected from cyclophosphamide, hydroxydaunorubicin (also referred to as doxorubicin or Adriamycin™) vincristine (also referred to as Oncovin™), prednisone, prednisolone, and combinations thereof.
37 . The method of claim 32 , wherein the at least one additional active agent is selected from the group consisting of ondansetron, granisetron, dolasetron and palonosetron.
38 . The method of claim 32 , wherein the at least one additional active agent is selected from the group consisting of pindolol and risperidone.
39 . The method of claim 32 , wherein the at least one additional active agent is rituximab.
40 . The method of claim 32 , wherein the at least one additional active agent is ibrutinib.